[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630031":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":36,"responsibleParty":52,"collaborators":55,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":60,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":30,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":82,"overallStatus":87,"whyStopped":30,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Dana-Farber Cancer Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"SHIELD Portal Interventional","EXPERIMENTAL","320 participants will be enrolled and will complete the following: Baseline visit (assessments) either by in-person clinic visit or virtually Follow-Up\u002FPost Baseline (3-month assessments) Medical record review (if necessary)",[13],"Behavioral: SHIELD portal",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BEHAVIORAL","SHIELD portal","All participants will receive access to the SHIELD portal. The portal includes educational modules, symptom and side effect tracking, tailored informational resources, and health behavior tools. Participants can access the portal via smartphone, tablet, or computer. The portal is HIPAA compliant and HITRUST certified.",[9],[21],"Supporting Health Including Endocrine Treatment for Long Duration (SHIELD) Portal",[23],{"name":24,"affiliation":5,"role":25},"Ann H Partridge, MD, MPH","PRINCIPAL_INVESTIGATOR",[27,32],{"name":24,"role":28,"phone":29,"phoneExt":30,"email":31},"CONTACT","617-632-6800",null,"ann_partridge@dfci.harvard.edu",{"name":33,"role":28,"phone":34,"phoneExt":30,"email":35},"Kate Dibble, Ph.D.","617-582-8294","katee_dibble@dfci.harvard.edu",[37],{"facility":5,"status":30,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Boston","Massachusetts","02215","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-71.05977,42.35843,{"lat":47,"lon":46},[50,51],{"name":24,"role":28,"phone":29,"phoneExt":30,"email":31},{"name":33,"role":28,"phone":34,"phoneExt":30,"email":35},{"type":25,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"Ann H. Partridge, MD, MPH","Principal Investigator",[56],{"name":57,"class":6},"Breast Cancer Research Foundation","100630031","supporting-health-including-endocrine-treatment-for-long-duration-100630031",false,"NCT07482384","Supporting Health Including Endocrine Treatment for Long Duration","Supporting Health Including Endocrine Treatment for Long Duration: A Pilot Intervention","SHIELD","Inclusion criteria\n\nParticipants will be eligible if they meet the following eligibility criteria:\n\n* Female\n* Age 18-49 years at diagnosis of a stage 0-IIIa, HR+ breast cancer\n* Premenopausal\n* In active treatment (including long-term endocrine therapy) at the time of enrollment\n* Able to speak, understand and read English\n* Access to a US-based mobile phone number\n* Cognitively able to complete study requirements\n* Ability to access medical records from treating hospital (DFCI)\n* Willing to provide cell phone number and\u002For email address and willing to receive email, mobile push notifications, and\u002For text messages from the study team\n\nExclusion criteria\n\nParticipants will be ineligible if they meet any of the following criteria:\n\n* Individuals under age 18 or over age 50 at initial breast cancer diagnosis\n* Patients with breast cancer who are not being treated with ET\n* Stage IV or metastatic breast cancer\n* Pregnant patients\n* Individuals who do not have a US mobile phone number\n* Males with breast cancer are not being recruited to this protocol. In the adolescent and young adult (AYA) age group, only a miniscule proportion of breast cancers occur in males. Additionally, this pilot focuses on breast cancer treatment utilizing OFS and ET, both of which do not apply to males. For this reason, the SHIELD portal intervention materials have been targeted for young women.","FEMALE","18 Years","49 Years",{"count":70,"type":71},30,"ESTIMATED","INTERVENTIONAL",[74],"NA","This research is being done to pilot an intervention which aims to test a new web- and mobile application (\"app\")-based supportive care tool (SHIELD portal) and to assess the feasibility of enrolling female breast cancer patients with hormone receptor-positive disease long-term endocrine treatment.",[77,78,79,80,81],"Breast Cancer","Breast Cancer - Female","Breast Carcinoma","ER Positive Breast Cancer","PR-Positive Breast Cancer",[83,84,85,86,64],"Breast cancer","Breast cancer female","Breast carcinoma","ER+","NOT_YET_RECRUITING","2026-03-16",{"date":90,"type":91},"2026-03-19","ACTUAL",{"date":93,"type":71},"2026-05",{"date":95,"type":71},"2027-05",{"name":5,"class":6},1]